FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Nashington,	D.C.	20549

)	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
---	--

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Prentiss Christopher B					2. Issuer Name and Ticker or Trading Symbol MANNKIND CORP [MNKD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) 1 CASPER	(Fir:	st) (Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/15/2024								X	below)		Other (spec below) ncial Officer		ресіту
(Street) DANBURY CT 06810			- 4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	<i>'</i>						
(City) (State) (Zip)				Rı	Rule 10b5-1(c) Transaction Indication														
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisful the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										satisfy									
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date			Date	Transaction ate Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispos			rities Acquired (A) or ed Of (D) (Instr. 3, 4 a				ly	Form:	Direct Indirect I	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) o (D)	r Price	е	Transactio	ion(s)			msu. 4)	
Common Stock, \$.01 Par Value			05/1	15/2024				A ⁽¹⁾⁽²⁾ 103,60		500 A		<mark>0</mark>	103,600		D				
Common Stock, \$.01 Par Value 05/15				5/2024				A ⁽¹⁾⁽³⁾		129,000 A		\$	6 <mark>0</mark>	232,600		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transaction Code (Instr. 8)				6. Date Exercis Expiration Date (Month/Day/Ye		of Securiti		ties ig e Security		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisal		Expiration Date	Title	Amoun or Numbe of Shar	er		(Instr. 4)			
Performance Restricted Stock Unit	(1)	05/15/2024			A		158,000		(4)		(4)	Common Stock, \$.01 Par Value	158,0	000	\$0.00	158,000		D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
- 2. 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is April 22, 2024.
- 3. Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2025 and each yearly anniversary thereof until fully vested.
- 4. The performance-based restricted stock unit will vest on July 15, 2027. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2024 until June 30, 2027 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.

05/17/2024 /s/ Christopher Prentiss

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.